GRAL stock news today

RBC Capital keeps Sector Perform on GRAIL, lifts target to $100

RBC Capital repeated its Sector Perform rating on GRAIL and raised its price target to $100. The update reflects the analyst's view on the stock.

RBC Lifts Its Target Price for GRAIL, Inc.

The firm RBC moved its target price higher for GRAIL, Inc. The change reflects the analyst's updated view of the shares.

Analyst raises GRAIL 12-month price target to $134.33

An analyst increased its 12-month price target for GRAIL to $134.33. The change reflects a revised outlook on the stock's value over the next year.

GRAIL Posts Q3 2026 Results

The company released its quarterly financial figures for the period ending in 2026. The filing covers its performance over those three months.

GRAIL's Galleri test to be carried by Felix Health

Felix Health will provide access to a blood-based screening test for multiple cancer types, made by GRAIL. The arrangement gives the test another route to patients.

Morgan Stanley keeps Equal-Weight on GRAIL, lifts target to $120

Morgan Stanley reaffirmed an Equal-Weight rating on GRAIL while raising its price target to $120. The update reflects the firm's latest view on the stock.

TD Cowen Keeps Buy Rating on GRAIL, Lifts Price Target to $180

TD Cowen reiterated its Buy rating on GRAIL and raised its price target to $180. The update reflects the firm's latest view on the stock.

New NHS-Galleri trial findings to be shared by GRAIL at two cancer meetings

GRAIL plans to disclose fresh results from its NHS-Galleri study at a cancer early detection event and the ESMO Congress. The data will be presented at both gatherings.

UBS keeps Buy rating on GRAIL, lifts price target to $175

UBS reiterated its Buy rating on GRAIL and increased its price target to $175. The update reflects the firm's latest view on the stock.

Guggenheim keeps Buy rating on GRAIL, lifts target to $155

Guggenheim reiterated its Buy rating on GRAIL and raised its price target to $155. The update reflects the firm's latest view on the stock.

Canaccord Genuity Keeps Buy Rating on GRAIL, Lifts Target to $150

Canaccord Genuity reiterated its Buy rating on GRAIL and increased its price target to $150. The move reflects the analyst's updated view on the stock.

Mizuho keeps Neutral rating on GRAIL, lifts price target to $100

Mizuho reiterated a Neutral rating on GRAIL while raising its price target to $100. The update reflects the firm's latest view on the stock.

FDA panel backs GRAIL's Galleri cancer screening test

An FDA advisory panel endorsed GRAIL's Galleri tool for cancer screening. The recommendation moves the test closer to potential regulatory clearance.

Baird keeps Outperform rating on GRAIL, lifts target to $118

Baird reiterated its Outperform rating on GRAIL and raised its price target to $118. The update reflects the firm's current view on the stock.

Grail Shares Jump After FDA Paper Notes Few False Positives, Strong Accuracy

A document from the FDA cited few incorrect positive results and strong accuracy, and this is tied to a rise in Grail's stock. The filing's contents are the stated reason for the share move.

FDA posts briefing documents for Grail's Galleri test review

The FDA released briefing documents ahead of a September 23 advisory committee meeting on Grail's Galleri cancer test. The documents raise no major concerns about the test.

RBC Capital starts GRAIL coverage with Sector Perform rating, $84 target

RBC Capital began covering GRAIL and set a Sector Perform rating with an $84 price target. The stock moved higher following the initiation.

RBC Capital starts GRAIL coverage with Sector Perform rating, $84 price target

RBC Capital began covering GRAIL and assigned a Sector Perform rating. The firm set a price target of $84 per share.

UBS starts GRAIL coverage with Buy rating, $105 price target

UBS began covering GRAIL and gave the shares a Buy rating. The firm set a price target of $105.

FDA advisory panel to assess GRAIL's request for clearance of its multi-cancer screening test

A panel of FDA advisers will review GRAIL's application seeking approval for a test that screens for several cancers at once. The meeting is part of the agency's review process.

What is the latest news on GRAL?

Nov 5, 2026: RBC Capital keeps Sector Perform on GRAIL, lifts target to $100 (Benzinga) · Nov 5, 2026: RBC Lifts Its Target Price for GRAIL, Inc. (Fiscal.ai) · Nov 5, 2026: Analyst raises GRAIL 12-month price target to $134.33 (Fiscal.ai)